ARD has publish a prospective, multicenter, observational study of vaccination outcomes in antineutrophil cytoplasmic antibodies associated vasculitis (AAV) patients, showing that AAV patients may not be adequately protected after standard two-dose COVID-19 vaccination, but that a third

The CDC's Advisory Committee on Immunization Practices (ACIP) recently recommended and approved two doses of the recombinant zoster vaccine (RZV, AKA Shingrix) for prevention of herpes zoster and complications in immunodeficient or immunosuppressed adults aged ≥19 years.

Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.

Today, UCB announced top-line interim analysis results from their Phase 3 "BE MOBILE 1" study, that demonstrated the efficacy of bimekizumab, a dual IL-17A and F inhibitor, in adults with active non-radiographic axial spondyloarthritis (nr-axSpA).

Lancet Rheumatology reports that a treat-to-target (T2T) goal of average serum urate less than 6 mg/dL is associated with an absence of gout flares and a reduction in the number of flares in the next 12 months.

While bisphosphonate drug holidays are recommended, there are few comparative studies.

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.

The results of the KEEPSaKE-1 study in psoriatic arthritis (PsA) has been published and shows that risankizumab (RIZ), an IL-23 inhibitor, showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD.

Follow-up in a Scandinavian cohort of juvenile idiopathic arthritis (JIA) patients that began in 1997-2000 revealed a number of surprises, a new study indicated.

A recent trial published in Annals of Internal Medicine analyzed the effects of B-cell depletion (rituximab) followed by B-cell suppression (belimumab) and showed effective lowering of anti-dsDNA titers and and fewer severe flare in patients with systemic lupus erythematosus (SLE).

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.